Explore AstraZeneca's strategic collaboration with CSPC Pharmaceuticals, focusing on AI-enabled drug discovery for chronic diseases, with potential milestones of over $5 billion.
Explore AstraZeneca PLC's June 2025 report detailing an insider transaction by CFO Aradhana Sarin, showcasing corporate governance through a charitable gift of shares.
Explore AstraZeneca PLC's Form 6-K detailing issued share capital, total voting rights, and regulatory compliance for investors and analysts.
Discover AstraZeneca's June 2025 Block Listing Interim Review, detailing securities management and share option plans. Key insights on compliance and financial performance.
AstraZeneca's Form 6-K reveals CEO Pascal Soriot's acquisition of 8,970 shares post-vesting. Key insights on performance, compliance, and tax obligations included.
AstraZeneca PLC's May 2025 Form 6-K details CEO Pascal Soriot's appointment to Agilent Technologies. Explore key insights on leadership changes and regulatory compliance.
Explore Gilead Sciences' Q1 2025 financial report, highlighting $6.647B revenue, $1.315B net income, and a positive outlook for investors. Key insights on profitability and R&D investments.
Explore Amgen Inc.'s Q1 2025 financial results showing 9.4% revenue growth, $1.73B net income, and effective debt management. A compelling buy recommendation for investors.
Explore Biogen's Q1 2025 financial results, showcasing $2.43B revenue growth, net income decline, and strategic restructuring for future profitability.
AstraZeneca PLC's recent Form 6-K reveals Non-Executive Director Karen Knudsen's purchase of 1,400 ADSs, reflecting confidence in the company's future. Key insights on compliance and market sentiment.
Explore AstraZeneca PLC's May 2025 Form 6-K report detailing 1.55B voting rights and regulatory compliance.
Explore key insights from AstraZeneca's 2025 AGM, highlighting shareholder support, board changes, and future outlook. Discover why we recommend a 'Hold' amid market uncertainties.